Is Altamira Therapeutics Stock a Good Investment?
Altamira Therapeutics Investment Advice | CYTO |
- Examine Altamira Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Altamira Therapeutics' leadership team and their track record. Good management can help Altamira Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Altamira Therapeutics' business and its evolving consumer preferences.
- Compare Altamira Therapeutics' performance and market position to its competitors. Analyze how Altamira Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Altamira Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Altamira Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Altamira Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Altamira Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Altamira Therapeutics Stock
Researching Altamira Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Altamira Therapeutics last dividend was issued on the 1st of May 2019. The entity had 1:20 split on the 13th of December 2023.
To determine if Altamira Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Altamira Therapeutics' research are outlined below:
| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Altamira Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeutics Ltd |
Altamira Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Altamira Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Altamira Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Altamira Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Altamira Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-31 | 2020-12-31 | -1.4 | -0.2869 | 1.1131 | 79 | ||
2020-09-17 | 2020-06-30 | -1.6 | -0.4041 | 1.1959 | 74 | ||
2019-03-14 | 2018-12-31 | -2.2173 | -0.6213 | 1.596 | 71 | ||
2017-11-28 | 2017-09-30 | -33 | -28.0 | 5.0 | 15 | ||
2016-11-10 | 2016-09-30 | -55.65 | -50.0 | 5.65 | 10 | ||
2017-08-10 | 2017-06-30 | -38 | -32.0 | 6.0 | 15 | ||
2016-05-11 | 2016-03-31 | -45.79 | -52.0 | -6.21 | 13 | ||
2018-11-15 | 2018-09-30 | -43.75 | -56.0 | -12.25 | 28 |
Know Altamira Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Altamira Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Altamira Therapeutics backward and forwards among themselves. Altamira Therapeutics' institutional investor refers to the entity that pools money to purchase Altamira Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 101.4 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.9 K | Ubs Group Ag | 2024-06-30 | 1.7 K | Group One Trading, Lp | 2024-06-30 | 14.0 | Lri Investments, Llc | 2024-06-30 | 1.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Altamira Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.52 M.Market Cap |
|
Altamira Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.91) | (2.01) | |
| Return On Capital Employed | (0.87) | (0.83) | |
| Return On Assets | (0.94) | (0.99) | |
| Return On Equity | (1.13) | (1.07) |
Determining Altamira Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Altamira Therapeutics is a good buy. For example, gross profit margin measures Altamira Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Altamira Therapeutics' profitability and make more informed investment decisions.
Evaluate Altamira Therapeutics' management efficiency
Altamira Therapeutics has return on total asset (ROA) of (0.5715) % which means that it has lost $0.5715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6878) %, meaning that it created substantial loss on money invested by shareholders. Altamira Therapeutics' management efficiency ratios could be used to measure how well Altamira Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -2.01. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Altamira Therapeutics' Debt To Assets are very stable compared to the past year. As of the 30th of November 2024, Asset Turnover is likely to grow to 0.05, while Total Assets are likely to drop about 7.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.15 | 12.50 | |
| Tangible Book Value Per Share | 5.22 | 4.96 | |
| Enterprise Value Over EBITDA | (0.68) | (0.71) | |
| Price Book Value Ratio | 0.22 | 0.23 | |
| Enterprise Value Multiple | (0.68) | (0.71) | |
| Price Fair Value | 0.22 | 0.23 | |
| Enterprise Value | 918.8 K | 872.9 K |
Understanding the operational decisions made by Altamira Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 2.442 |
Basic technical analysis of Altamira Stock
As of the 30th of November, Altamira Therapeutics shows the Mean Deviation of 3.53, standard deviation of 4.7, and Risk Adjusted Performance of (0.17). Altamira Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Altamira Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Altamira Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Altamira Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Altamira Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lokay Kevin G over two weeks ago Acquisition by Lokay Kevin G of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 | ||
Carter Stephen over a month ago Disposition of 10000 shares by Carter Stephen of Altamira Therapeutics at 0.62 subject to Rule 16b-3 | ||
Mollica Joseph A over three months ago Acquisition by Mollica Joseph A of 198 shares of Altamira Therapeutics subject to Rule 16b-3 | ||
Schnittker Christopher P over six months ago Acquisition by Schnittker Christopher P of 18000 shares of Altamira Therapeutics at 5.15 subject to Rule 16b-3 | ||
Schnittker Christopher P over six months ago Acquisition by Schnittker Christopher P of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 |
Altamira Therapeutics' Outstanding Corporate Bonds
Altamira Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Altamira Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Altamira bonds can be classified according to their maturity, which is the date when Altamira Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Altamira Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Altamira Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | (5.00) | |||
| Mean Deviation | 3.53 | |||
| Coefficient Of Variation | (417.71) | |||
| Standard Deviation | 4.7 | |||
| Variance | 22.12 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (1.16) | |||
| Total Risk Alpha | (1.92) | |||
| Treynor Ratio | (5.01) | |||
| Maximum Drawdown | 22.81 | |||
| Value At Risk | (10.87) | |||
| Potential Upside | 6.98 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.7093 |
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | (5.00) | |||
| Mean Deviation | 3.53 | |||
| Coefficient Of Variation | (417.71) | |||
| Standard Deviation | 4.7 | |||
| Variance | 22.12 | |||
| Information Ratio | (0.27) | |||
| Jensen Alpha | (1.16) | |||
| Total Risk Alpha | (1.92) | |||
| Treynor Ratio | (5.01) | |||
| Maximum Drawdown | 22.81 | |||
| Value At Risk | (10.87) | |||
| Potential Upside | 6.98 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.7093 |
Consider Altamira Therapeutics' intraday indicators
Altamira Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Altamira Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Altamira Therapeutics time-series forecasting models is one of many Altamira Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Altamira Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Altamira Stock media impact
Far too much social signal, news, headlines, and media speculation about Altamira Therapeutics that are available to investors today. That information is available publicly through Altamira media outlets and privately through word of mouth or via Altamira internal channels. However, regardless of the origin, that massive amount of Altamira data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Altamira Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Altamira Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Altamira Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Altamira Therapeutics alpha.
Altamira Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Altamira Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Altamira Therapeutics Corporate Management
| Covadonga Paeda | Chief Officer | Profile | |
| Covadonga Paneda | Chief Officer | Profile | |
| Jean Lechance | Unit Bus | Profile | |
| Samuel MD | Chief Officer | Profile | |
| Marcel CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Altamira Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.